18918 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health

Written Question

Published date: 24 May 2026

Metadata

Document type:	Written Question
Parliament number:	54
Question number:	18918 (2026)
Question asked:	10 May 2026
Member asking:	Hon Dr Ayesha Verrall
Portfolio:	Associate Minister of Health
Minister replying:	Hon David Seymour
Answer received:	19 May 2026
Status:	Question Answered
Reply type:	Reply
Document ID:	WQ_18918_2026
Document guid:	d3e53ffe-8c61-4721-97a5-e7fef0495189

18918 (2026). Hon Dr Ayesha Verrall to the Associate Minister of Health: Has ibrutinib been funded by Pharmac for the treatment of relapsed or refractory mantle cell lymphoma; and if not, is it under consideration for funding?

Hon David Seymour: No, ibrutinib is not currently funded by Pharmac for the treatment of relapsed or refractory mantle cell lymphoma. I am advised by Pharmac that ibrutinib has been assessed and added to the Options for Investment List, and may be considered for funding should sufficient budget become available. I refer the Member to the following link for more information: https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puXu/p001189